RecruitingNot ApplicableNCT04024631

Phenotyping Genetic Risk for Type 2 Diabetes

Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes


Sponsor

University of Pennsylvania

Enrollment

100 participants

Start Date

Jun 17, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.


Eligibility

Min Age: 10 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how genetic risk factors translate into physical differences in metabolism — specifically glucose and insulin responses — in people at elevated genetic risk for type 2 diabetes. The goal is to identify who is at highest risk before they develop the disease. **You may be eligible if...** - You are between 10 and 70 years old - You previously participated in the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be re-contacted - Adults must have a BMI of 25 or higher; children and adolescents must have a BMI at or above the 85th percentile **You may NOT be eligible if...** - You already have a diagnosis of type 1, type 2, or any other form of diabetes - You take medications that affect blood sugar (such as metformin, steroids, or other diabetes drugs) - You are pregnant - You have anemia, gastrointestinal problems affecting absorption, or another serious medical condition - You recently received chemotherapy Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER75g glucose beverage (Glucola, Trutol, or similar brand)

Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.

OTHERDXA, whole body

Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.


Locations(2)

Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04024631


Related Trials